Activation of DNA damage checkpoint pathways, including Chk2, serves as an anticancer barrier in precancerous lesions. In an effort to identify small-molecule activators of Chk2, the authors developed a quantitative cell-based assay using a highcontent analysis (HCA) platform. Induction of phosphorylated Chk2 was evaluated using several different parameters, including fold induction, Kolmogorov-Smirnov score, and percentage of positively stained cells. These measurements were highly correlated and provided an accurate method for compound ranking/binning, structure-activity relationship studies, and lead identification. Screening for Chk2 activators was undertaken with a target-focused library and a diversified library from ArQule chemical space. Several compounds exhibited submicromolar EC 50 values for phosphorylated Chk2 induction. These compounds were further analyzed for Chk2-dependent cytotoxicity, as assessed through a high-content cell death assay in combination with siRNA silencing of Chk2 expression. Several compounds were identified and showed specific inhibition or lethality in a target-dependent manner. Therefore, identification of DNA damage checkpoint pathway activators by HCA is an attractive approach for discovering the next generation of targeted cancer therapeutics. (Journal of Biomolecular Screening 2008:538-543) 
INTRODUCTION
S ELECTIVE KILLING OF TUMOR CELLS by chemotherapeutics represents a real challenge to clinical cancer treatment. 1 The first generation of effective cancer drugs has mainly targeted DNA synthesis and microtubule machinery and still forms the basis of most chemotherapeutic regimens. 2 However, severe side effects and clinical resistance have limited their application. As a result, current cancer drug discovery has focused primarily on identification of agents that target disease-causing oncogenic factors for hypothesis-driven, mechanism-based molecular therapeutics. 3 The DNA damage response pathway coordinates the activation of highly conserved signal transduction pathways that enable cells to either repair the damage or activate a programmed cell death process when the damage is irreversible. 4 Sensors such as ATM and ATR work together with downstream mediators (BRCA1, MDC1, and others), transducers (Chk1, Chk2), and effectors (p53, E2F1, and others) to prevent the transmission of damaged chromosomes to daughter cells. It has been well documented that ATM-and ATR-mediated phosphorylation trigger the activation of Chk2 and Chk1, respectively. Chk1 and Chk2 further activate downstream substrates to functionally regulate cell cycle control, DNA repair activation, genome stability, and apoptosis.
Most recently, the DNA damage response has been reported to be a primary barrier to tumorigenesis and disease progression in early cancer development. 5, 6 Elevated levels of phosphorylated ATM and Chk2 were observed in early lesions from various tumor samples. 5, 6 These DNA damage response pathway markers are detected in precancerous lesions, suggesting that human cells activate DNA damage response pathways to delay or prevent tumorigenesis. The human checkpoint kinase Chk2 plays a central role in response to DNA damage insults and telomere erosion. 7 Activated Chk2 induced by DNA damage signals can trigger a block in cell cycle progression and initiate DNA damage repair. Therefore, extensive efforts have been made to develop Chk2 inhibitors to enhance the apoptotic response to chemotherapy or radiation by suppressing DNA repair mechanisms. 8 Another approach is to directly activate Chk2 (through phosphorylation) in cancer cells, thus inducing checkpoint-mediated apoptosis. Data from our laboratory have shown that Chk2 expression/phosphorylation is sufficient to induce apoptotic cell death in p53-null cancer cell lines, 9 providing the proof of concept for Chk2 activators as anticancer therapeutics. 10 High-content analysis (HCA) is an image-based methodology for the simultaneous detection of multiple cellular parameters in live or fixed cells. 11 Multichannel fluorescent signals can be quantitatively measured at the single-cell level, which is conducive for the analysis of complicated signal transduction pathways and/or intracellular networks, especially when throughput is of consideration. Recent development in HCA instrumentation and analysis software allows its application in almost every phase of the drug discovery process, including primary and secondary screening, hit to lead and lead optimization, and in vitro toxicology profiling. 12, 13 In combination with RNAi technology, HCA has become an unparalleled method for genome-wide screening and validation of therapeutic targets. 14 The goal of this study was to identify small-molecule Chk2 activators for use as targeted cancer therapies. A high-throughput, cellbased, high-content fluorescent assay is reported here for compound screening/EC 50 determination of phosphorylated Chk2 activation (P-Chk2) to replace labor-intensive assays such as Western blotting. To accurately quantify the fluorescent signal generated by P-Chk2 staining, we adopted 3 different parameters, including fold induction, Kolmogorov-Smirnov (KS) scoring, and percentage of positively stained cells. We believe that our screening strategy can be generally applicable to all cell-based HCA assays.
MATERIALS AND METHODS

Cell culture and reagents
Hela, Paca-2, A549, DU-145, and DLD-1 cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA). All cancer cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS; v/v), 10 mM L-glutamine, and 10 mM HEPES. Subcultured cells within 10 passages were routinely used for HCA assays.
All reagents were of analytical grade or comparable. Chk2 (Ser68) polyclonal antibody was obtained from Cell Signal Technology (Catalog #2661L, Danvers, MA). Rhodaminelabeled antirabbit antibodies were purchased from Jackson ImmunoResearch (Catalog #711-295-152, West Grove, PA). Annexin V-FITC and propidium iodide (PI) were obtained from Roche Applied Science (Indianapolis, IN). Paraformaldehyde was purchased from Molecular Probes (Eugene, OR).
Compound libraries preparation and management
The target-focused library and the diversified library were made in-house. Compounds in master plates were prepared at a concentration of 3 mM (for screening plates) or 30 mM (for EC 50 plates, in column 2 for a 10-point serial dilution) in DMSO in V-bottomed 96-well plates (Costar 3363). All compounds were routinely checked for solubility and purity. Positive controls were designated in column 1, whereas DMSO controls were in column 7. Copies of daughter plates were stored at -20 °C for repeated testing.
High-content screening assay for P-Chk2 staining
Hela cells were seeded in Costar 96-well assay plates (Costar 3603) at a density of 16,000 cells/well approximately 16 to 24 h before compound treatment. The overall dilution of compound in DMEM was 300-fold, with a final concentration of 10 μM for screening and a serially diluted concentration ranging between 100 μM and 5 nM (10 assayed points) for EC 50 determination (final DMSO concentration is 0.3% v/v). All liquid-handling procedures were performed using a Rapid Plate 384 (Caliper Life Sciences, Hopkinton, MA) and Sciclone ALH 3000 (Caliper Life Sciences). Two hours after compound addition, 50 μL of paraformaldehyde was mixed with the culture medium (total volume at 150 μL) to a final concentration of 4%. The plates were incubated at room temperature for exactly 10 min before washing with phosphate-buffered saline (PBS). Permeablization of cellular membrane was achieved using 0.2% Triton X-100 in PBS for 5 min. After washing 3 times with PBS, 80 μL of 5% FBS/PBS was applied to the plate at room temperature for 30 min. For antibody staining, a 1:500 dilution of anti-P-Chk2 antibody in 5% FBS/PBS was added to the plates. The plates were incubated at room temperature for 2 h or at 4 °C overnight. Finally, a mixture of secondary antibody and DAPI was added into the plates at a final concentration of 1:5000 (for DAPI at 5 mg/mL), 1:1000 (for rhodamine-labeled antirabbit secondary antibody). After 1 h at room temperature, the plates were washed with PBS and stored at 4 °C.
Image acquisition and analysis were performed using a Cell Lab IC 100 Image Cytometer (Beckman Coulter, Fullerton, CA) and an INcell 1000 (GE Healthcare, Piscataway, NJ) integrated with a Twister II robot for automated plate delivery. For the IC100, the program was set to capture 4 images per well at 16.7 ms/30% gain for the DAPI channel and 2000 ms/50% gain for the rhodamine channel. For INcell 1000, the setting was also 4 images captured per well at 20 ms for DAPI and 200 ms for rhodamine. Image analysis was carried out using Cytoshop 2.1 (for IC100) and Workstation 3.4 (for INcell 1000). Algorithms for data analysis were established and optimized according to assay conditions and manufacture instructions. KS score was calculated using Pipeline Pilot (Scitegic, San Diego, CA) with a custom written software component. EC 50 values and curve fitting were performed using Prism 4.0 (GraphPad Software, San Diego, CA) with a nonlinear regression model, where the EC 50 value equals the concentration at which the inflection point of the fitted model is reached.
High-content cell death assay
Paca-2 cells were plated at 8000/well. Serially diluted compounds were added and incubated for 4 h at 37 °C (final DMSO concentration is 0.3% v/v). Cells were labeled with 1:200 Annexin V-FITC (Roche Applied Science) and 1 μg/mL propidium iodide (Invitrogen, Carlsbad, CA). High-content image acquisition was performed using INcell Analyzer 1000. The program was set to take 4 images per well with exposure time indicated above. Image analysis was carried out with the Multi Target Analysis assay in Workstation software version 3.4 (GE Healthcare).
Chk2 siRNA knockdown
Paca-2 cells were plated as described previously. SMARTpool Chk2 siRNA (Dharmacon, Lafayette, CO) was prepared according to the manufacturer's instructions. Briefly, 25 nM siRNA with DharmaFECT1 (Dharmacon) was applied to the plates at 37 °C in 5% CO 2 for 48 h. Serially diluted compounds were then added to the plates and incubated for 2 h. Dead cancer cells were labeled with propidium iodide as previously reported. Image acquisition and analysis were carried out using the same settings.
RESULTS AND DISCUSSION
Quantification of nuclear P-Chk2 signal
One compound from the target-focused library was previously found to induce P-Chk2 in multiple cancer cells, including Hela (Fig. 1A, control compound) . Figure 1B shows that a majority of the Hela cells treated with this compound for 2 h were stained as P-Chk2 positive cells ( Fig. 1B, color in red) . As compared with the DMSO-treated samples (Fig. 1C) , a profound increase in fluorescence signal was observed in the rhodamine channel. Fold induction was introduced to quantitatively calculate signal induction using the following formula: fold induction = average value of AFU Compound /average value of AFU DMSO . Because Chk2 and P-Chk2 primarily reside in the nucleus, the value of AFU is the mean nuclear pixel value in the rhodamine (for P-Chk2) channel. After further optimization of the assay conditions, the fold induction value for P-Chk2 of this compound at a 2-h treatment time was 10.89 ± 2.26. This compound was chosen as a positive control for P-Chk2 induction in our assays.
To validate our assay, we selected a set of 80 compounds from the target-focused library that were structurally related to the positive control as a test compound set. As shown in Figure  2A , a wide distribution of P-Chk2 induction was observed in this compound set with satisfactory dynamic range (0 to more than 70-fold). This result further confirms that assay conditions were optimized to properly rank compounds according to their fold induction value. The key factor for development of this assay was to tightly control fluorescent background contributed by the DMSO-treated samples. The average value of the DMSO well is a major determinant of the induction values of assayed compounds as well as coefficient of variation (CV) values of the data. We routinely checked DMSO background signal such that the average AFU from the DMSO well was around or below 10. The assay was also found to be robust for automated operation with a Z′ of 0.6.
We further validated the P-Chk2 assay by introducing a parameter called the KS score. The Kolmogorov-Smirnov test , and AQ4 at 10 μM for 2 h at 37 °C. Actin serves as loading control. For the high-content analysis (HCA) study, Hela cells were prepared with 16,000 cells/well and treated by (B) an ArQule positive control compound and (C) a DMSO negative control at 10 μM for 2 h at 37 °C. Cells were fixed and stained with an anti-P-Chk2 antibody followed by treatment with a rhodamine (red) labeled secondary antibody. Nuclear chromosomes were stained using DAPI (blue). The images were captured in a Beckman Coulter/IC100 with a 10× objective.
is a sensitive statistical test used to quantitatively compare a given tested compound well with DMSO control wells in the same plate, which returns a single value (KS score) per well. The KS score is a value between 0 and 1 describing whether the compound-treated sample is identical (0) or distinct (1) from the DMSO control sample. The advantage of the KS test can be summarized in the following 3 parts: (1) the cell population in a specific well is treated as an integrated body, which largely overcomes the potential drawbacks of fold induction (by taking the average AFU value of the whole population). (2) The KS test is independent of population size. This feature makes it an attractive analysis tool for cancer drug discovery because cell number may reduce significantly after compound treatment. (3) The KS test does not assume any model distribution associated with the data, presenting a friendly method to handle data from high-content screening. KS scores for the 80-compound test set were calculated using pipeline pilot with customized algorithms. As shown in Figure 2B , a satisfactory correlation of fold induction value with KS score was observed (R 2 = 0.88), suggesting that the P-Chk2 assay with the parameter of fold induction was optimized for large-scale screening.
Screening results: target-focused library versus diversified library
Compound libraries were screened at a final concentration of 10 μM for P-Chk2 activation with the target-focused library and the diversified library in Hela cells. When we use 10 as the cutoff value (fold induction for the assay positive control is 10), more than 40% of the compounds (128 compounds in a collection of 298 compounds, hit rate of 42.95%) in the targetfocused library exhibited strong P-Chk2 induction at 2 h, indicating a highly enriched compound pool for Chk2 activators. In comparison, 39 compounds showed more than 10-fold induction in the diversified library with a hit rate of 2.05%. Several compounds from 6 different chemotypes showed satisfactory induction of P-Chk2 levels (data not shown).
Seven positive hits identified from the target-focused library and the diversified library were chosen to further examine their P-Chk2 induction level in multiple cancer cell lines. Higher fold induction of P-Chk2 was observed in human pancreatic cell line Paca-2, Hela, and DU145 cell lines (Fig. 3A) . The human colorectal cell line DLD-1 contains 1 CHK2 allele with an inactivating point mutation (R145W), whereas the other allele is transcriptionally silenced, rendering the cells Chk2 deficient. 15 As expected, no Chk2 induction was recorded in DLD-1 cell lines (Fig. 3A) . Selected compounds were further examined for their EC 50 value for P-Chk2 induction. Figure 3B shows dose-response curves for 3 selected compounds. The EC 50 values were determined by using 9 concentration points ranging from 5 nM to 33 μM for AQ6 or using 10 concentration points from 0.6 nM to 11 μM for AQ1 and AQ2. This assay was performed with the INcell 1000 instrument, which is not capable of background subtraction, thus making the calculation of fold induction impossible. Instead, the images were processed with a customized threshold set to calculate the percentage of P-Chk2 positively stained cells. This threshold value was defined as the percentage of cells in the compound-treated wells with an average nuclear P-Chk2 signal larger than that of DMSO-treated wells plus 2 folds of standard deviation. Two potent Chk2 activators (AQ1 and AQ2) were identified and confirmed with nanomolar EC 50 values (Fig. 3B) .
Chk2 gene silencing by siRNA and cytotoxic protection
It is particularly important to determine whether Chk2 activation contributes to compound-induced cytotoxicity in tumor cells. Synthetic siRNA at high doses can introduce undesired off-target effects. However, incubation for 48 h with 25 nM Chk2 siRNA can completely knock down Chk2 expression with no significant loss of cell number, suggesting an optimal condition for gene silencing (data not shown). When the P-Chk2-inducing compound AQ2 was applied to both control and Chk2 knockdown cells, a more than 45-fold increase of EC 50 value for the induction of cell death (PI positively stained cells) was observed ( Fig. 4A) . At a compound concentration of 11 μM, more than 80% of control siRNA-treated cells were dead, whereas few PI positive cells were recorded in the Chk2 siRNAtreated sample (Fig. 4B, C) . We also performed Western blot analysis to confirm siRNA knockdown of Chk2. Significant reduction of the P-Chk2 signal was observed in samples treated with the selected compounds when Paca-2 cells were pretreated with Chk2 siRNA (Fig. 4D) . In summary, our results suggest that cytotoxic effects are the direct consequence of Chk2 induction. Further study on mechanisms of action will expand our current knowledge of how checkpoint pathway activation prevents malignant proliferation.
